ID   PLD4_HUMAN              Reviewed;         506 AA.
AC   Q96BZ4; Q6UWD2;
DT   20-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   16-MAY-2006, sequence version 2.
DT   18-JUN-2025, entry version 166.
DE   RecName: Full=5'-3' exonuclease PLD4 {ECO:0000305};
DE            EC=3.1.16.1 {ECO:0000250|UniProtKB:Q8BG07};
DE   AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD4 {ECO:0000305|PubMed:39423811};
DE            EC=3.1.4.- {ECO:0000269|PubMed:39423811};
DE   AltName: Full=Phospholipase D family member 4;
DE   AltName: Full=Phospholipase D4;
GN   Name=PLD4 {ECO:0000303|PubMed:30111894, ECO:0000312|HGNC:HGNC:23792};
GN   Synonyms=C14orf175; ORFNames=UNQ2488/PRO5775;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30111894; DOI=10.1038/s41590-018-0179-y;
RA   Gavin A.L., Huang D., Huber C., Maartensson A., Tardif V., Skog P.D.,
RA   Blane T.R., Thinnes T.C., Osborn K., Chong H.S., Kargaran F., Kimm P.,
RA   Zeitjian A., Sielski R.L., Briggs M., Schulz S.R., Zarpellon A.,
RA   Cravatt B., Pang E.S., Teijaro J., de la Torre J.C., O'Keeffe M.,
RA   Hochrein H., Damme M., Teyton L., Lawson B.R., Nemazee D.;
RT   "PLD3 and PLD4 are single-stranded acid exonucleases that regulate
RT   endosomal nucleic-acid sensing.";
RL   Nat. Immunol. 19:942-953(2018).
RN   [4]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=34620855; DOI=10.1038/s41467-021-26150-w;
RA   Gavin A.L., Huang D., Blane T.R., Thinnes T.C., Murakami Y., Fukui R.,
RA   Miyake K., Nemazee D.;
RT   "Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory
RT   triggering by multiple sensors.";
RL   Nat. Commun. 12:5874-5874(2021).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND SUBUNIT.
RX   PubMed=38697119; DOI=10.1016/j.immuni.2024.04.010;
RA   Berouti M., Lammens K., Heiss M., Hansbauer L., Bauernfried S., Stoeckl J.,
RA   Pinci F., Piseddu I., Greulich W., Wang M., Jung C., Froehlich T.,
RA   Carell T., Hopfner K.P., Hornung V.;
RT   "Lysosomal endonuclease RNase T2 and PLD exonucleases cooperatively
RT   generate RNA ligands for TLR7 activation.";
RL   Immunity 57:1482-1496.e8(2024).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   HIS-214; LYS-216; ASP-221; VAL-426; HIS-428 AND GLU-435.
RX   PubMed=39423811; DOI=10.1016/j.cell.2024.09.036;
RA   Singh S., Dransfeld U.E., Ambaw Y.A., Lopez-Scarim J., Farese R.V. Jr.,
RA   Walther T.C.;
RT   "PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid
RT   degradation in lysosomes.";
RL   Cell 0:0-0(2024).
RN   [7] {ECO:0007744|PDB:8V08}
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 60-506, DISULFIDE BOND, ACTIVE
RP   SITE, SUBUNIT, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF LEU-183; VAL-212;
RP   HIS-214; ASP-221; ARG-235; HIS-252; GLN-255; SER-283; ALA-326; PHE-348;
RP   GLY-368; HIS-428; GLU-435 AND ALA-497.
RX   PubMed=38537643; DOI=10.1016/j.str.2024.02.019;
RA   Yuan M., Peng L., Huang D., Gavin A., Luan F., Tran J., Feng Z., Zhu X.,
RA   Matteson J., Wilson I.A., Nemazee D.;
RT   "Structural and mechanistic insights into disease-associated endolysosomal
RT   exonucleases PLD3 and PLD4.";
RL   Structure 32:766-779.e7(2024).
CC   -!- FUNCTION: 5'->3' exonuclease that hydrolyzes the phosphodiester bond of
CC       single-stranded DNA (ssDNA) and RNA molecules to form nucleoside 3'-
CC       monophosphates and 5'-end 5'-hydroxy deoxyribonucleotide/ribonucleotide
CC       fragments (PubMed:30111894, PubMed:34620855, PubMed:38537643,
CC       PubMed:39423811). Partially redundant with PLD3, can cleave all four
CC       nucleotides displaying higher efficiency for ssDNA and RNA fragments
CC       initiated with uridine and guanosine residues and lower efficiency for
CC       cytidine-initiated substrates (PubMed:30111894, PubMed:34620855,
CC       PubMed:38537643, PubMed:39423811). As a result, it does not always
CC       degrade polynucleotides to the single nucleotide level, it can stall at
CC       specific sites sparing certain fragments from exonucleolytic
CC       degradation (PubMed:30111894, PubMed:34620855, PubMed:38537643,
CC       PubMed:39423811). Processes self and pathogenic ssDNA and RNA molecules
CC       that reach the endolysosomal compartment via phagocytosis or autophagy
CC       and may serve as 'danger' signals for recognition by innate immune
CC       receptors such as toll-like receptors (TLRs) (PubMed:38697119).
CC       Degrades mitochondrial CpG-rich ssDNA fragments to prevent TLR9
CC       activation and autoinflammatory response, but it can cleave viral RNA
CC       to generate ligands for TLR7 activation and initiate antiviral immune
CC       responses (PubMed:38697119). In plasmacytoid dendritic cells, it
CC       cooperates with endonuclease RNASET2 to release 2',3'-cyclic guanosine
CC       monophosphate (2',3'-cGMP), a potent stimulatory ligand for TLR7
CC       (PubMed:38697119). Produces 2',3'-cGMPs and cytidine-rich RNA fragments
CC       that occupy TLR7 ligand-binding pockets and trigger a signaling-
CC       competent state (PubMed:38697119). Can exert polynucleotide phosphatase
CC       activity toward 5'-phosphorylated ssDNA substrates although at a slow
CC       rate (PubMed:38537643). Transphosphatidylase that catalyzes the
CC       exchange with R to S stereo-inversion of the glycerol moiety between
CC       (S,R)-lysophosphatidylglycerol (LPG) and monoacylglycerol (MAG)
CC       substrates to yield (S,S)-bis(monoacylglycero)phosphate (BMP)
CC       (PubMed:39423811). Can synthesize a variety of (S,S)-BMPs representing
CC       the main phospholipid constituent of lysosomal intralumenal vesicle
CC       (ILV) membranes that bind acid hydrolases for lipid degradation
CC       (PubMed:39423811). Regulates the homeostasis and interorganellar
CC       communication of the endolysosomal system with an overall impact on
CC       cellular removal of dysfunctional organelles via autophagy as well as
CC       proper protein and lipid turnover. May play a role in myotube formation
CC       in response to ER stress (By similarity).
CC       {ECO:0000250|UniProtKB:Q8IV08, ECO:0000269|PubMed:30111894,
CC       ECO:0000269|PubMed:34620855, ECO:0000269|PubMed:38537643,
CC       ECO:0000269|PubMed:38697119, ECO:0000269|PubMed:39423811}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Exonucleolytic cleavage in the 5'- to 3'-direction to yield
CC         nucleoside 3'-phosphates.; EC=3.1.16.1;
CC         Evidence={ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:34620855,
CC         ECO:0000269|PubMed:38537643, ECO:0000269|PubMed:38697119};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-dephospho-ribonucleotidyl-ribonucleotide-RNA + H2O
CC         = a ribonucleoside 3'-phosphate + a 5'-end dephospho-ribonucleoside-
CC         RNA + H(+); Xref=Rhea:RHEA:81375, Rhea:RHEA-COMP:13936, Rhea:RHEA-
CC         COMP:19670, ChEBI:CHEBI:13197, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:138284, ChEBI:CHEBI:231871;
CC         Evidence={ECO:0000269|PubMed:34620855};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81376;
CC         Evidence={ECO:0000305|PubMed:34620855};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ribonucleoside 3'-phosphate-2'-3'-cyclophospho-GMP + H2O = a
CC         ribonucleoside 3'-phosphate + 2',3'-cyclophospho-GMP + H(+);
CC         Xref=Rhea:RHEA:81319, ChEBI:CHEBI:13197, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:60837, ChEBI:CHEBI:231870;
CC         Evidence={ECO:0000269|PubMed:38697119};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81320;
CC         Evidence={ECO:0000269|PubMed:38697119};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-dephospho-2'-deoxyribonucleotidyl-2'-
CC         deoxyribonucleotide in single-stranded DNA + H2O = a 5'-end
CC         dephospho-2'-deoxyribonucleoside in single-stranded DNA + a 2'-
CC         deoxyribonucleoside 3'-phosphate + H(+); Xref=Rhea:RHEA:81379,
CC         Rhea:RHEA-COMP:19701, Rhea:RHEA-COMP:19702, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:131705, ChEBI:CHEBI:136416,
CC         ChEBI:CHEBI:231873; Evidence={ECO:0000269|PubMed:30111894,
CC         ECO:0000269|PubMed:38537643};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81380;
CC         Evidence={ECO:0000305|PubMed:30111894, ECO:0000305|PubMed:34620855,
CC         ECO:0000305|PubMed:38537643};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-phospho-2'-deoxyribonucleotide in single-stranded
CC         DNA + H2O = a 5'-end 5'-dephospho-2'-deoxyribonucleotide in single-
CC         stranded DNA + phosphate; Xref=Rhea:RHEA:82335, Rhea:RHEA-COMP:19868,
CC         Rhea:RHEA-COMP:19869, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:136412, ChEBI:CHEBI:136416;
CC         Evidence={ECO:0000269|PubMed:38537643};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82336;
CC         Evidence={ECO:0000305|PubMed:38537643};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3-lyso-sn-glycero-1-phospho-(3'-acyl-1'-sn-glycerol) + a 1-
CC         acyl-sn-glycerol = a 3-acyl-sn-glycero-1-phospho-(3'-acyl-1'-sn-
CC         glycerol) + glycerol; Xref=Rhea:RHEA:82563, ChEBI:CHEBI:17754,
CC         ChEBI:CHEBI:64683, ChEBI:CHEBI:77717, ChEBI:CHEBI:232393;
CC         Evidence={ECO:0000269|PubMed:39423811};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82564;
CC         Evidence={ECO:0000305|PubMed:39423811};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-lyso-sn-glycero-1-phospho-(3'-(9Z-octadecenoyl)-1'-sn-
CC         glycerol) + 1-(9Z-octadecenoyl)-sn-glycerol = 3-(9Z-octadecenoyl)-sn-
CC         glycero-1-phospho-(3'-(9Z-octadecenoyl)-1'-sn-glycerol) + glycerol;
CC         Xref=Rhea:RHEA:82567, ChEBI:CHEBI:17754, ChEBI:CHEBI:75757,
CC         ChEBI:CHEBI:139150, ChEBI:CHEBI:232394;
CC         Evidence={ECO:0000269|PubMed:39423811};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82568;
CC         Evidence={ECO:0000305|PubMed:39423811};
CC   -!- ACTIVITY REGULATION: The exonuclease activity toward ssDNA substrate is
CC       Ca(2+) and Mg(2+)-independent, but it is inhibited by Fe(2+), Cu(2+)
CC       and to a lesser extent Zn(2+) ions. {ECO:0000269|PubMed:38537643}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimally active at acidic pHs. {ECO:0000269|PubMed:38537643};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:38697119}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:Q8BG07}; Single-pass type II membrane protein
CC       {ECO:0000250|UniProtKB:Q8BG07}. Golgi apparatus, trans-Golgi network
CC       membrane {ECO:0000250|UniProtKB:Q8BG07}; Single-pass type II membrane
CC       protein {ECO:0000250|UniProtKB:Q8BG07}. Nucleus
CC       {ECO:0000250|UniProtKB:Q8BG07}. Early endosome
CC       {ECO:0000250|UniProtKB:Q8BG07}. Cytoplasmic vesicle, phagosome
CC       {ECO:0000250|UniProtKB:Q8BG07}. Lysosome {ECO:0000269|PubMed:39423811}.
CC       Note=Activation of microglia induces translocation of PLD4 from the
CC       nucleus to the phagosomes. {ECO:0000250|UniProtKB:Q8BG07}.
CC   -!- TISSUE SPECIFICITY: Expressed in plasmacytoid dendritic cells and
CC       monocytes (at protein level). {ECO:0000269|PubMed:38697119}.
CC   -!- DOMAIN: The catalytic domain contains two conserved PLD
CC       phosphodiesterase HxK(x4)D(E) motifs that accomodate the phosphate
CC       group of the nucleic acid substrates, with one nucleophile histidine
CC       residue forming a phosphohistidine intermediate and the other histidine
CC       protonating the leaving 5'-OH ssDNA/RNA fragment, resulting in the
CC       cleavage of the phosphodiester bond. The homodimer has two independent
CC       catalytic domains arranged at the dimer interface.
CC       {ECO:0000269|PubMed:38537643}.
CC   -!- PTM: Highly N-glycosylated. {ECO:0000250|UniProtKB:Q8BG07}.
CC   -!- SIMILARITY: Belongs to the phospholipase D family. {ECO:0000305}.
CC   -!- CAUTION: Exhibits no phospholipase activity, despite two HKD motifs.
CC       {ECO:0000250|UniProtKB:Q8BG07}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ89202.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY358843; AAQ89202.1; ALT_INIT; mRNA.
DR   EMBL; BC015003; AAH15003.2; -; mRNA.
DR   CCDS; CCDS9995.2; -.
DR   RefSeq; NP_620145.2; NM_138790.5.
DR   PDB; 8V08; X-ray; 3.00 A; A/B=60-506.
DR   PDBsum; 8V08; -.
DR   AlphaFoldDB; Q96BZ4; -.
DR   SMR; Q96BZ4; -.
DR   BioGRID; 125782; 81.
DR   FunCoup; Q96BZ4; 219.
DR   IntAct; Q96BZ4; 1.
DR   STRING; 9606.ENSP00000438677; -.
DR   BindingDB; Q96BZ4; -.
DR   ChEMBL; CHEMBL4879501; -.
DR   GlyConnect; 1605; 8 N-Linked glycans (5 sites).
DR   GlyCosmos; Q96BZ4; 9 sites, 9 glycans.
DR   GlyGen; Q96BZ4; 11 sites, 12 N-linked glycans (5 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; Q96BZ4; -.
DR   PhosphoSitePlus; Q96BZ4; -.
DR   BioMuta; PLD4; -.
DR   DMDM; 121944492; -.
DR   MassIVE; Q96BZ4; -.
DR   PaxDb; 9606-ENSP00000376372; -.
DR   PeptideAtlas; Q96BZ4; -.
DR   ProteomicsDB; 76132; -.
DR   Antibodypedia; 28277; 179 antibodies from 26 providers.
DR   DNASU; 122618; -.
DR   Ensembl; ENST00000392593.9; ENSP00000376372.5; ENSG00000166428.14.
DR   GeneID; 122618; -.
DR   KEGG; hsa:122618; -.
DR   MANE-Select; ENST00000392593.9; ENSP00000376372.5; NM_138790.5; NP_620145.2.
DR   UCSC; uc001ypu.2; human.
DR   AGR; HGNC:23792; -.
DR   CTD; 122618; -.
DR   DisGeNET; 122618; -.
DR   GeneCards; PLD4; -.
DR   HGNC; HGNC:23792; PLD4.
DR   HPA; ENSG00000166428; Tissue enhanced (bone marrow, brain, lymphoid tissue).
DR   MIM; 618488; gene.
DR   neXtProt; NX_Q96BZ4; -.
DR   OpenTargets; ENSG00000166428; -.
DR   PharmGKB; PA134861676; -.
DR   VEuPathDB; HostDB:ENSG00000166428; -.
DR   eggNOG; KOG3603; Eukaryota.
DR   GeneTree; ENSGT00950000183059; -.
DR   HOGENOM; CLU_027021_0_0_1; -.
DR   InParanoid; Q96BZ4; -.
DR   OrthoDB; 1923775at2759; -.
DR   PAN-GO; Q96BZ4; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; Q96BZ4; -.
DR   TreeFam; TF313378; -.
DR   PathwayCommons; Q96BZ4; -.
DR   Reactome; R-HSA-1483148; Synthesis of PG.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   BioGRID-ORCS; 122618; 13 hits in 1147 CRISPR screens.
DR   ChiTaRS; PLD4; human.
DR   GenomeRNAi; 122618; -.
DR   Pharos; Q96BZ4; Tbio.
DR   PRO; PR:Q96BZ4; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q96BZ4; protein.
DR   Bgee; ENSG00000166428; Expressed in granulocyte and 107 other cell types or tissues.
DR   ExpressionAtlas; Q96BZ4; baseline and differential.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0045335; C:phagocytic vesicle; ISS:UniProtKB.
DR   GO; GO:0032588; C:trans-Golgi network membrane; ISS:UniProtKB.
DR   GO; GO:0045145; F:single-stranded DNA 5'-3' DNA exonuclease activity; ISS:UniProtKB.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006909; P:phagocytosis; ISS:UniProtKB.
DR   GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; ISS:UniProtKB.
DR   CDD; cd09148; PLDc_vPLD4_2; 1.
DR   FunFam; 3.30.870.10:FF:000013; phospholipase D3 isoform X1; 1.
DR   FunFam; 3.30.870.10:FF:000019; phospholipase D3 isoform X1; 1.
DR   Gene3D; 3.30.870.10; Endonuclease Chain A; 2.
DR   InterPro; IPR050874; Diverse_PLD-related.
DR   InterPro; IPR032803; PLDc_3.
DR   InterPro; IPR001736; PLipase_D/transphosphatidylase.
DR   PANTHER; PTHR10185:SF8; 5'-3' EXONUCLEASE PLD4; 1.
DR   PANTHER; PTHR10185; PHOSPHOLIPASE D - RELATED; 1.
DR   Pfam; PF13918; PLDc_3; 1.
DR   SMART; SM00155; PLDc; 2.
DR   SUPFAM; SSF56024; Phospholipase D/nuclease; 2.
DR   PROSITE; PS50035; PLD; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasmic vesicle; Disulfide bond; Endoplasmic reticulum;
KW   Endosome; Exonuclease; Glycoprotein; Golgi apparatus; Hydrolase; Immunity;
KW   Inflammatory response; Innate immunity; Lipid metabolism; Lysosome;
KW   Membrane; Nuclease; Nucleus; Phospholipid metabolism;
KW   Proteomics identification; Reference proteome; Repeat; Signal-anchor;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..506
FT                   /note="5'-3' exonuclease PLD4"
FT                   /id="PRO_0000280333"
FT   TRANSMEM        31..51
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          209..236
FT                   /note="PLD phosphodiesterase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   DOMAIN          423..449
FT                   /note="PLD phosphodiesterase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        214
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153,
FT                   ECO:0000305|PubMed:38537643"
FT   ACT_SITE        216
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        221
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        428
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000305|PubMed:38537643"
FT   CARBOHYD        150
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        171
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        249
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        281
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        403
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        417
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        427
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        444
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   DISULFID        94..250
FT                   /evidence="ECO:0000269|PubMed:38537643,
FT                   ECO:0007744|PDB:8V08"
FT   DISULFID        379..502
FT                   /evidence="ECO:0000269|PubMed:38537643,
FT                   ECO:0007744|PDB:8V08"
FT   VARIANT         16
FT                   /note="C -> R (in dbSNP:rs894037)"
FT                   /id="VAR_061751"
FT   VARIANT         27
FT                   /note="E -> Q (in dbSNP:rs2841280)"
FT                   /id="VAR_031119"
FT   VARIANT         135
FT                   /note="V -> M (in dbSNP:rs3803295)"
FT                   /id="VAR_031120"
FT   MUTAGEN         183
FT                   /note="L->G: Loss of exonuclease activity toward ssDNA
FT                   substrate."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         212
FT                   /note="V->A: Loss of exonuclease activity toward ssDNA
FT                   substrate; when associated with A-348."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         214
FT                   /note="H->A: Loss of exonuclease and phosphatase activities
FT                   toward ssDNA; when associated with A-414. Loss of (S,S)-BMP
FT                   synthase activity. No effect on protein expression or
FT                   localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:38537643,
FT                   ECO:0000269|PubMed:39423811"
FT   MUTAGEN         216
FT                   /note="K->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         221
FT                   /note="D->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes. Loss of
FT                   protein stability; when associated with A-435."
FT                   /evidence="ECO:0000269|PubMed:38537643,
FT                   ECO:0000269|PubMed:39423811"
FT   MUTAGEN         235
FT                   /note="R->Q: Tends to form aggregates. Loss of exonuclease
FT                   activity toward ssDNA substrate."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         252
FT                   /note="H->Q: No effect on exonuclease activity toward ssDNA
FT                   substrate."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         255
FT                   /note="Q->L: No effect on exonuclease activity toward ssDNA
FT                   substrate."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         283
FT                   /note="S->L: Tends to form aggregates. Decreases
FT                   exonuclease activity toward ssDNA substrate."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         326
FT                   /note="A->V: No effect on exonuclease activity toward ssDNA
FT                   substrate."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         348
FT                   /note="F->A: Loss of exonuclease activity toward ssDNA;
FT                   when associated with A-212."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         368
FT                   /note="G->S: Increases exonuclease activity toward ssDNA
FT                   substrate."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   MUTAGEN         426
FT                   /note="V->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         428
FT                   /note="H->A: Loss of exonuclease and phosphatase
FT                   activities; when associated with A-414. Loss of (S,S)-BMP
FT                   synthase activity. No effect on protein expression or
FT                   localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:38537643,
FT                   ECO:0000269|PubMed:39423811"
FT   MUTAGEN         435
FT                   /note="E->A: Loss of (S,S)-BMP synthase activity. No effect
FT                   on protein expression or localization to lysosomes. Loss of
FT                   protein stability; when associated with A-221."
FT                   /evidence="ECO:0000269|PubMed:38537643,
FT                   ECO:0000269|PubMed:39423811"
FT   MUTAGEN         435
FT                   /note="E->D: No effect on (S,S)-BMP synthase activity,
FT                   protein expression or localization to lysosomes."
FT                   /evidence="ECO:0000269|PubMed:39423811"
FT   MUTAGEN         497
FT                   /note="A->V: No effect on exonuclease activity toward ssDNA
FT                   substrate."
FT                   /evidence="ECO:0000269|PubMed:38537643"
FT   STRAND          95..101
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           118..128
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          133..136
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   TURN            145..147
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           154..169
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          175..179
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           189..194
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   TURN            195..197
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          199..202
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           205..209
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          217..220
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   TURN            221..223
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          224..229
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          232..234
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           235..238
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          239..249
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           251..253
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           254..267
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   TURN            280..282
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          288..290
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          302..309
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           310..312
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           320..330
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          332..340
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           357..368
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          372..379
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          381..383
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           387..395
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           400..402
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          404..412
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          421..423
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          425..427
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          431..433
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          435..443
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          445..447
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   TURN            448..452
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          453..461
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   HELIX           473..485
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          486..492
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   TURN            493..495
FT                   /evidence="ECO:0007829|PDB:8V08"
FT   STRAND          498..501
FT                   /evidence="ECO:0007829|PDB:8V08"
SQ   SEQUENCE   506 AA;  55626 MW;  D7F820C83131FE26 CRC64;
     MLKPLWKAAV APTWPCSMPP RRPWDREAGT LQVLGALAVL WLGSVALICL LWQVPRPPTW
     GQVQPKDVPR SWEHGSSPAW EPLEAEARQQ RDSCQLVLVE SIPQDLPSAA GSPSAQPLGQ
     AWLQLLDTAQ ESVHVASYYW SLTGPDIGVN DSSSQLGEAL LQKLQQLLGR NISLAVATSS
     PTLARTSTDL QVLAARGAHV RQVPMGRLTR GVLHSKFWVV DGRHIYMGSA NMDWRSLTQV
     KELGAVIYNC SHLAQDLEKT FQTYWVLGVP KAVLPKTWPQ NFSSHFNRFQ PFHGLFDGVP
     TTAYFSASPP ALCPQGRTRD LEALLAVMGS AQEFIYASVM EYFPTTRFSH PPRYWPVLDN
     ALRAAAFGKG VRVRLLVGCG LNTDPTMFPY LRSLQALSNP AANVSVDVKV FIVPVGNHSN
     IPFSRVNHSK FMVTEKAAYI GTSNWSEDYF SSTAGVGLVV TQSPGAQPAG ATVQEQLRQL
     FERDWSSRYA VGLDGQAPGQ DCVWQG
//
